Preclinical evaluation of DISC-GMCSF for the treatment of breast carcinoma

Journal of Gene Medicine

Volumn 5, Issue 5, 2003, Pages 407-416

  Loudon, Peter T ^a   McLean, Cornelia S ^a   Martin, Gilly ^a   Curry, Jayne ^a,c   Shaw, M Leigh ^a,d   Hoogstraten, Conny ^b   Verdegaal, Els ^b   Osanto, Susanne ^b  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ASTEX PHARMACEUTICALS   (United Kingdom)

^d Huntington Life Sciences Ltd   (United Kingdom)

Author keywords

Breast cancer; Gene therapy; GM CSF; HSV vectors; Murine tumour model

Indexed keywords

BETA GALACTOSIDASE; ENDOSTATIN; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GREEN FLUORESCENT PROTEIN; ANTINEOPLASTIC ANTIMETABOLITE; PHOTOPROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER MODEL; CELL COUNT; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFICACY; GENE EXPRESSION; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH; VIRAL GENE THERAPY; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL SEPARATION; CENTRIFUGATION; EXPERIMENTAL NEOPLASM; FEMALE; FLOW CYTOMETRY; GENE THERAPY; GENE VECTOR; GENETICS; METABOLISM; METHODOLOGY; MOUSE; PHENOTYPE; TIME; TUMOR CELL LINE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SEPARATION; CENTRIFUGATION; FEMALE; FLOW CYTOMETRY; FLUOROURACIL; GENE THERAPY; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; GREEN FLUORESCENT PROTEINS; HERPESVIRUS 2, HUMAN; HUMANS; LUMINESCENT PROTEINS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; PHENOTYPE; TIME FACTORS;

EID: 1542466854     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.354     Document Type: Article

References (22)

1. Anon. Cancer facts and figures. American Cancer Society Inc, Atlanta, GA, USA, 2001; 10.
2. Patton S, Gendler SJ, Spicer AP. The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim Biophys Acta 1995; 1241: 407-423. Review.
3. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
4. Ballesta AM, Molina R, Filella X, Jo J, Gimenez N. Carcinoembryonic antigen in staging and follow-up of patients with solid tumors. Tumour Biol 1995; 16: 32-41. Review.
5. Schlom J, Kantor J, Abrams S, Tsang KY, Panicali D, Hamilton JM. Strategies for the development of recombinant vaccines for the immunotherapy of breast carcinoma. Breast Carcinoma Res Treat 1996; 38: 27-39. Review.
6. Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res 2000; 6: 1347-1350.
7. Jiang XP, Yang DC, Elliott RL, Head JF. Vaccination with a mixed vaccine of autogenous and allogeneic breast carcinoma cells and tumor associated antigens CA15-3, CEA and CA125-results in immune and clinical responses in breast carcinoma patients. Cancer Biother Radiopharm 2000; 15: 495-505.
8. Feuerer M, Beckhove P, Bai L, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001; 7: 452-458.
9. Boursnell ME, Entwisle C, Blakeley D, et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 1997; 175: 16-25.
10. Todryk S, McLean C, Ali S, et al. Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer. Hum Gene Ther 1999; 10: 2757-2768.
11. Ali SA, McLean CS, Boursnell ME, et al. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes. Cancer Res 2000; 60: 1663-1670.
12. Loudon PT, Blakeley DM, Boursnell ME, et al. Preclinical safety testing of DISC-hGMCSF to support phase I clinical trials in cancer patients. J Gene Med 2001; 3: 458-467.
13. Heppner GH, Miller FR, Malathy Shekhar P, et al. Non-transgenic models of breast carcinoma. Breast Carcinoma Res 2000; 2: 331-334.
14. Lohr F, Hu K, Haroon Z, et al. Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. Mol Ther 2000; 2: 195-203.
15. Nicola NA. Granulocyte-macrophage colony stimulating factor. In Guidebook to Cytokines and Their Receptors. Oxford University Press: Oxford, 1994; 171-173.
16. Nyberg-Hoffman C, Shabram P, Li W, et al. Sensitivity and reproducibility in adenoviral infectious titre determination. Nat Med 1997; 3: 808-811.
17. Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997; 57: 1537-1546.
18. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90: 3539-3543.
19. Vial T, Descotes J. Clinical toxicity of cytokines used as haemopoietic growth factors. Drug Safety 1995; 13: 371-406.
20. Mastrangelo MJ, Maguire HC, Eisenlohr LC, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999; 6: 409-422.
21. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7 867-874.
22. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000; 7: 859-866.